Back to Journals » Clinical Ophthalmology » Volume 7

Comparison of Placido disc and Scheimpflug image-derived topography-guided excimer laser surface normalization combined with higher fluence CXL: the Athens Protocol, in progressive keratoconus

Authors Kanellopoulos J , Asimellis G

Received 4 March 2013

Accepted for publication 6 April 2013

Published 18 July 2013 Volume 2013:7 Pages 1385—1396

DOI https://doi.org/10.2147/OPTH.S44745

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3



Video abstract presented by Anastasios John Kanellopoulos

Views: 4457

Anastasios John Kanellopoulos,1,2 George Asimellis1

1Laservision.gr Eye Institute, Athens, Greece; 2New York University School of Medicine, Department of Opthalmology, NY, NY, USA

Background: The purpose of this study was to compare the safety and efficacy of two alternative corneal topography data sources used in topography-guided excimer laser normalization, combined with corneal collagen cross-linking in the management of keratoconus using the Athens protocol, ie, a Placido disc imaging device and a Scheimpflug imaging device.
Methods: A total of 181 consecutive patients with keratoconus who underwent the Athens protocol between 2008 and 2011 were studied preoperatively and at months 1, 3, 6, and 12 postoperatively for visual acuity, keratometry, and anterior surface corneal irregularity indices. Two groups were formed, depending on the primary source used for topoguided photoablation, ie, group A (Placido disc) and group B (Scheimpflug rotating camera). One-year changes in visual acuity, keratometry, and seven anterior surface corneal irregularity indices were studied in each group.
Results: Changes in visual acuity, expressed as the difference between postoperative and preoperative corrected distance visual acuity were +0.12 ± 0.20 (range +0.60 to -0.45) for group A and +0.19 ± 0.20 (range +0.75 to -0.30) for group B. In group A, K1 (flat keratometry) changed from 45.202 ± 3.782 D to 43.022 ± 3.819 D, indicating a flattening of -2.18 D, and K2 (steep keratometry) changed from 48.670 ± 4.066 D to 45.865 ± 4.794 D, indicating a flattening of -2.805 D. In group B, K1 (flat keratometry) changed from 46.213 ± 4.082 D to 43.190 ± 4.398 D, indicating a flattening of -3.023 D, and K2 (steep keratometry) changed from 50.774 ± 5.210 D to 46.380 ± 5.006 D, indicating a flattening of -4.394 D. For group A, the index of surface variance decreased to -5.07% and the index of height decentration to -26.81%. In group B, the index of surface variance decreased to -18.35% and the index of height decentration to -39.03%. These reductions indicate that the corneal surface became less irregular (index of surface variance) and the “cone” flatter and more central (index of height decentration) postoperatively.
Conclusion: Of the two sources of primary corneal data, the Scheimpflug rotating camera (Oculyzer™) for topography-guided normalization treatment with the WaveLight excimer laser platform appeared to provide more statistically significant improvement than the Placido disc topographer (Topolyzer™). Overall, the Athens protocol, aiming both to halt progression of keratoconic ectasia and to improve corneal topometry and visual performance, produced safe and satisfactory refractive, keratometric, and topometric results. The observed changes in visual acuity, along with keratometric flattening and topometric improvement, are suggestive of overall postoperative improvement.

Keywords: Athens protocol, anterior Pentacam indices, keratoconus, cross-linking, WaveLight/Alcon excimer laser, EX500 excimer laser, higher fluence collagen cross-linking

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.